Our growing understanding of the molecular landscape of pediatric ependymomas, posterior-fossa A ependymoma, posterior fossa B ependymoma, supratentorial ependymoma, ZFTA fusion-positive (formerly called RELA fusion-positive), supratentorial ependymoma, and YAP1 fusion-positive [22] has helped refine prognostic factors but has not yet impacted treatment strategies. The gene discussed is YAP1; the disease is supratentorial ependymoma.